Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage by Stam, T.C. (Tanja) et al.
Systemic Toxicity and Cytokine/Acute Phase Protein Levels in
Patients After Isolated Limb Perfusion With Tumor Necrosis
Factor-a Complicated by High Leakage
Tanja C. Stam, MD, Anton J. G. Swaak, MD, PhD, Mark R. de Vries, MD,
Timo L. M. ten Hagen, PhD, and Alexander M. M. Eggermont, MD, PhD
Background: Since the introduction of high-dose tumor necrosis factor-a (TNFa) in the setting
of isolated limb perfusion (ILP) in the clinic, prevention of leakage to the body of the patient is
monitored with great precision for fear of TNF-mediated toxicity. That we observed remarkably
little toxicity in patients with and without leakage prompted us to determine patterns of cytokines
and acute phase proteins in patients with high leakage and in patients without any leakage.
Methods: TNFa, interleukin (IL)-6, IL-8, C-reactive protein, and secretory (s)-phospholipase A2 were
measured at several time points during and after (until 7 days) ILP in 10 patients with a leakage to the
systemic circulation varying in percentage from 12% to 65%. As a control, the same measurements, both
in peripheral blood and in perfusate, were performed in nine patients without systemic leakage.
Results: In patients with systemic leakage, levels of TNFa increased during ILP, reaching values
to 277 ng/ml. IL-6 and IL-8 peaked 3 hours after ILP with values significantly higher compared with
patients without systemic leakage. C-reactive protein and s-phospholipase A2 peaked at day 1 in
both patient groups, s-phospholipase A2 with significant higher levels and C-reactive protein, in
contrast, with lower levels in the leakage patients.
Conclusions: High leakage of TNFa to the systemic circulation, caused by a complicated ILP,
led to 10-fold to more than 100-fold increased levels of TNFa, IL-6, and IL-8 in comparison with
patients without leakage. The increase of the acute phase proteins was limited. Even when high
leakage occurs, this procedure should not lead to fatal complications. The most prominent clinical
toxicity was hypotension (grade III in four patients), which was easily corrected. No pulmonary or
renal toxicity was observed in any patient. It is our experience that, even in the rare event of
significant leakage during a TNFa-based ILP, postoperative toxicity is usually mild and can be
easily managed by the use of fluid and, in some cases, vasopressors.
Key Words: Isolated limb perfusion—TNFa—Leakage—Toxicity—Secondary cytokine re-
sponse—Acute phase response.
The technique of regional isolated limb perfusion
(ILP) with the use of an extracorporeal circuit was pio-
neered by Creech and co-workers.1 The advantage of this
treatment modality is that a high dose of cytostatic drug
can be delivered to the tumor-bearing extremity without
producing systemic side effects. ILP permits regional
cytostatic concentrations 15 to 20 times higher than those
reached after systemic administration.2 The standard
drug in this setting is melphalan (L-phenyl-alaninemus-
tard). In patients with multiple melanoma in-transit me-
tastases, an ILP with melphalan results in about 50% of
the patients in a complete remission.3 Addition of tumor
necrosis factor-a (TNFa) to melphalan has proven most
effective in terms of response rate, yielding a 80% to
90% complete response rate and an overall response of
about 100%.4,5 In locally advanced soft-tissue sarcomas,
the use of TNFa in combination with melphalan has
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proven remarkably effective in rendering irresectable
tumors resectable and thereby preventing amputations.5,6
The efficacy of TNF against the drug-resistant soft-tissue
sarcomas has led to the approval of TNF by the EMEA
(European Medicine Evaluation Agency) for its use in
combination with melphalan.7
In the ILP system, TNFa is administered in a 10-fold
higher dose compared with the maximum tolerable dose
in systemic administration. The maximum tolerable dose
of TNFa in single-dose intravenous or intramuscular
administration is limited by toxicity at 400 mg/m2.8,9
Toxicity consists of fever, hypotension, chills, and tran-
sient leukopenia. Hardly any tumor response has been
reported after systemic administration of TNFa.9–11
Despite careful precautions, systemic leakage of more
than 10% appeared in 10 patients during the last 6 years
in our hospital. These patients had a remarkably mild
clinical course. To get more insight into the cause of this
discrepancy between the high systemic concentration of
TNFa and the mild clinical symptoms, we studied cyto-
kine levels and the acute phase response.
PATIENTS AND METHODS
Patients
From the 212 patients who underwent an ILP with
TNFa and melphalan in the past 8 years in our hospital,
10 patients were selected because of very high systemic
levels of TNFa caused by leakage from the perfusate.
These patients were treated because of an irresectable
sarcoma (n 5 6) or melanoma with multiple in-transit
metastases (n 5 4). Demographic and treatment charac-
teristics are summarized in Table 1. As a control group,
we studied nine comparable patients undergoing ILP
without systemic leakage. These patients were all sar-
coma patients, who underwent a 90-minute ILP with 3 to
4 mg of TNFa. The mean age was 48 years (range,
21–77 years).
Treatment Schedule
The procedure of ILP has been described previously.5
In brief, ILP consisted of a 90-minute-long perfusion
with 3 to 4 mg of recombinant human TNFa (Boehringer
Ingelheim, Alkmaar, The Netherlands) and 10 to 13
mg/liter perfusion tissue of melphalan (Alkeran; Bur-
roughs Wellcome, London, UK) at mild hyperthermia
(39°C to 40°C). Composition of the perfusate was as
follows: priming volume of 700 to 850 ml consisted of
400 to 500 ml of blood (50% red blood cells/50% plas-
ma), 200 to 400 ml of 5% dextran-40 in glucose 5%
(Isodex; Pharmacia, Uppsala, Sweden), 10 to 30 ml of
8.4% sodium bicarbonate, and 0.5 ml of 2500 to 5000 IU
heparin. TNFa was injected as a bolus into the arterial
line if limb tissue temperature was .38°C. Melphalan
was administered 30 minutes later at limb temperatures
between 39°C to 40°C. At the end of perfusion, the limb
was washed with at least 2 liters of 6% dextran-70
(Macrodex; Pharmacia). During and after ILP, vital signs
of the patients, including body temperature, heart rate,
blood pressure, and fluid balance, were recorded. Tox-
icity was registered according to the World Health Or-
ganization criteria.12
Leakage Monitoring
During ILP, there was a dynamic balance between two
pressure compartments, the systemic vasculature and the
isolated circuit, which could be influenced by adjusting
the systemic blood pressure and/or the extracorporeal
flow rate. Throughout the perfusion period, any potential
leakage of the drugs was monitored by using a radioac-
tive tracer. A small calibration dose of human serum
albumin radiolabeled with iodine 131 or technetium 99m
was injected into the systemic circulation and a 10-fold
higher dose of the same isotope into the isolated extrem-
ity. Continuous monitoring was performed with a pre-
cordial scintillation probe. Systemic leakage was ex-
TABLE 1. Patient characteristics
Patient
no. Age, y Sex Diagnosis Arm/leg
Duration of
perfusion,
min
Dose
(mg of TNFa) Leak, %
Maximum systemic
TNF (ng/ml)
1 55 F Sarcoma Leg 90 2 23 169
2 52 F Melanoma Leg 90 4 20 178
3 66 M Sarcoma Arm 90 3 12 30
4 61 F Sarcoma Arm 30 3 65 277
5 71 F Melanoma Leg 90 2 24 112
6 56 M Sarcoma Leg 90 2 15 77
7 65 M Melanoma Leg 90 2 32 108
8 64 F Melanoma Leg 90 4 13 104
9 83 M Sarcoma Leg 75 4 19 174
10 55 F Sarcoma Leg 90 4 16 90
TNF, tumor necrosis factor.
269HIGH LEAKAGE OF TNFa DURING ILP
Ann Surg Oncol, Vol. 7, No. 4, 2000
pressed quantitatively as a percentage such that 100%
leakage represented a homogeneous distribution of the
isotope in the body.
Blood Sampling Procedure
Venous blood samples were collected at several time
points, i.e., the day before ILP, just before administration
of TNFa in the perfusate, halfway perfusion, and just
before release of the tourniquet (after completion of the
washout procedure at the end of the perfusion); then after
ILP, 5, 10, and 30 minutes, and 3 and 7 hours after
release of the tourniquet, and once a day until 7 days
after ILP. Samples from the perfusate were obtained at
the following times: 0 (just before administration of
TNFa) and 10, 30, 60, and 90 minutes after administra-
tion of TNFa. Blood samples were immediately centri-
fuged; plasma was collected and stored at 270°C until
tested.
Assays for Cytokine and Acute Phase Protein
Analysis
Cytokine and acute phase protein (APP) levels were
measured by using an enzyme-linked immunosorbent
assay (ELISA). Used antibodies were obtained from the
Central Laboratory of the Blood Transfusion Service
(Amsterdam, The Netherlands). For measuring TNFa, as
described previously,13 flat-bottomed microtiter plates
(Nunc, Kamstrup, Denmark) were coated overnight with
purified monoclonal antibody (mAb) against TNFa
(CLB-TNF/7). After washing, serial dilutions of TNF-
containing samples were added. Bound TNFa was de-
tected by biotinylated sheep anti-TNFa. The detection
limit of the assay was 5 pg/ml. Healthy controls were at
less than 5 pg/ml. The IL-6-specific ELISA has been
described previously.14 A coat of CLB-IL-6/16 was ap-
plied overnight, and bound IL-6 was detected by biotin-
ylated affinity-purified polyclonal sheep anti-IL-6. A
lower detection limit was 1 pg/ml, and normal healthy
control subjects were at less than 10 pg/ml.
For IL-8, a coat of CLB-IL-8/1 mAb was applied
overnight and bound IL-8 was detected by biotinylated
affinity-purified polyclonal sheep anti-IL-8. The lower
detection limit of this assay was 8 pg/ml. Normal values
were at less than 20 pg/ml.15
C-reactive protein (CRP) levels were measured by a
sandwich ELISA, using polyclonal rabbit anti-human
CRP Abs as catching Abs and biotinylated mAb anti-
CRP (CLB anti-CRP-2) as a detecting Ab. Results were
referred to a standard (Behringwerke AG, Marburg, Ger-
many) and expressed as milligrams per liter. The detec-
tion limit was 10 ng/liter.16
The ELISA used for measuring s-phospholipase A2
(sPLA2) has been described before.17 Two different
mAbs against human sPLA2 were used as coating and
catching antibodies respectively. The lower limit of de-
tection was 0.1 ng/ml. Normal healthy volunteers were at
less 5 ng/ml.
Statistics
Median values are expressed with range. Comparison
between the cytokine and APP levels in the two groups
(with and without leakage) were made by the Mann-
Whitney U test. Values of P 5 .05 were considered to be
statistically significant.
RESULTS
Systemic Toxicity
Ten patients with a systemic leakage percentage of
more than 10% were entered onto this study. Leakage
varied from 12% to 65% (mean, 24%; Table 1).
Because of expected toxicity, all patients are well
monitored at our intensive care unit postoperatively.
Systemic toxicity is summarized in Table 2. During ILP,
blood pressure and pulse rate remained stable with ade-
quate fluid management. The body temperature did not
increase above 38°C. After ILP, all patients received
indomethacin to suppress flu-like symptoms. Eight of 10
patients developed fever grade II (38°C to 40°C) within
TABLE 2. Systemic toxicity after ILP in the 10 patients
with leakage to the systemic circulation compared with 9
patients without leakage
Toxicity (WHO grade)
Grade 0–I Grade II Grade III Grade IV
Leakage
Fever 2 8 0 0
Hypotension 3 3 4 0
Leukocytesa 8 0 1 1
Plateletsb 6 3 0 1
Bilirubinc 3 3 4 0
ASAT/ALATd 7 3 0 0
Nausea 8 2 0 0
Nonleakage
Fever 6 3 0 0
Hypotension 9 0 0 0
Leukocytes 9 0 0 0
Platelets 9 0 0 0
Bilirubin 9 0 0 0
ASAT/ALAT 9 0 0 0
Nausea 8 1 0 0
WHO, World Health Organization; ASAT, aspartate aminotransfer-
ase; ALAT, alanine aminotransferase.
a Grade III: 0–1.9 3 109/liter; grade IV: ,1.0 3 109/liter.
b Grade II: 50–74 3 109/liter; grade IV: ,25 3 109/liter.
c Grade II: 2.6–5 3 N; grade III: 5.1–10 3 N (N 5 upper limit of
normal value).
d Grade II: 2.6–5 3 N.
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a few hours after ILP (mean maximal temperature,
38.9°C). In the patients without detectable leakage, the
mean maximal temperature was 38.1°C. In four leakage
patients, the heart rate increased to more than 110 beats
per minute (range, 120–132 beats per minute). Four
patients had a hypotension, which was not quickly re-
stored to normal values by fluid administration alone,
and required additional treatment with dopamine (3–6
mg/kg/min) for 2 to 3 days. From the start of surgery, a
mean of 8 liters was administered to the leakage patients
during the first 16 hours vs. 5 liters for nonleakage
patients. Leukopenia and thrombocytopenia was absent
or mild. Grade IV leukopenia and thrombocytopenia in
one patient was induced by leakage of melphalan. No
transfusion was required. Patients without leakage did
not develop hematological toxicity. All leakage patients
had a hyperbilirubinemia after 2 days, and the transami-
nases increased (grade I-II). In the no-leakage group,
only 1 patient had a mild hyperbilirubinemia.
No pulmonary or renal toxicity was observed in any
patient.
Plasma Cytokine and APP Levels
In Fig. 1, median values with ranges were represented
for the cytokines TNFa and IL-6 and the APPs CRP and
sPLA2. Median peak levels of all measured cytokines
and APPs in both patient groups, depicted in Table 3,
were significantly different (P values in Table 3). Be-
cause we know the curves of IL-8 and sPLA2 from
previous published experiments,18,19 we restricted the
determinations to the preoperative and the maximum
level time points.
In the leakage group, very high circulating concentra-
tions of TNFa are found during perfusion (at 245 min-
utes), in contrast to the nondetectable TNFa levels in
patients without leakage. Plateau circulating concentra-
tions are measured at the end of the perfusion, lasting up
to 30 minutes after ILP. The small amount of TNFa that
remains in the limb after the washout procedure does not
increase the colossal systemic levels any further in these
patients, in contrast to what is observed in patients with-
out leakage. There we observed a brief peak of systemic
levels more than 100-fold less than in leakage patients.
Moreover, the peak occurs typically at 5 to 10 minutes
after ILP and represents the TNFa that was left behind in
the limb after the washout. TNF levels decreased already
after 30 minutes, because rapid clearance of this cytokine
with a short half-life time of 17 minutes is operational.
Thus, in leakage patients, very high TNF concentrations
are present for about 4 hours, whereas a very short peak
of 20 to 30 minutes of “moderate” increased TNF levels
is present in leakage-free patients. There was a strict
correlation between the degree of leakage estimated by
isotope monitoring, the (adjusted) dose of TNFa, and the
measured maximum systemic levels of TNFa, depicted
in Table 1.
IL-6 increased already during perfusion in leakage
patients, immediately induced by TNFa. In the nonleak
patients, IL-6 increased 5 to 10 minutes after ILP, i.e.,
after TNFa from the washed out limb appeared in the
systemic circulation. Maximum values of IL-6 were
reached 3 hours after ILP. IL-8 showed the same pattern
as IL-6 (data not shown). In the control group, values of
IL-6 and IL-8 were 10 to 60 times lower than in the
leakage patients.
The APP CRP was increased from 3 hours after ILP
until more than 7 days after ILP. Peak levels occurred at
day 1. The CRP curve in patients without leakage was
comparable, but the peak value was higher. Levels of
sPLA2 were very different for each patient. However, the
pattern was consistent, with the start of the increase at 3
hours after ILP and the peak at day 1. Levels were still
increased after 7 days. Levels in the nonleakage patients
were factor 6 lower.
Levels of Cytokines and APPs in Perfusate
No significant difference was observed in perfusate
levels of cytokines and APPs in patients who underwent
ILP with systemic leakage and without leakage. From the
ILP patients with systemic leakage, only five series of
perfusate samples were available. Curves are presented
in Fig. 2. TNF levels remained stable at approximately
7.5 mg/ml. IL-6 increased after 10 minutes of perfusion,
to 4.3 ng/ml at the end of perfusion. IL-8 increased from
65 to 1600 pg/ml during perfusion. CRP did not change
during perfusion, with values hardly detectable or at less
than the detection limit. In three of five patients, sPLA2
increased during perfusion; the median value at the end
of perfusion was 14 ng/ml and the range, 8.5 to 266
ng/ml.
DISCUSSION
The aim of our study was to quantify cytokine levels
and acute phase response in patients who underwent an
ILP with high-dose TNFa complicated by high leakage,
compared with the same variables in patients without
leakage, and correlate findings with clinical toxicity. In
this study, we measured TNFa plasma levels up to 277
ng/ml. Nevertheless, most of the patients needed only
extra intravenous fluid administration. Systemic levels of
this magnitude have been described before in the same
setting20,21 and once after a 30-minute intravenous infu-
sion of recombinant TNFa.22
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FIG. 1. Median (with range) of tumor necrosis factor (TNF) (A), interleukin (IL)-6 (B), and C-reactive protein (CRP) and s-phospholipase A2
(sPLA2) (C) in plasma from 10 patients who underwent an isolated limb perfusion (ILP) complicated by high leakage (.12%) to the systemic blood
circulation. For TNF (L; A), IL-6 (M; B), and CRP (E; C), the curves of the nonleakage group are also depicted. Time points were as follows: pre,
preoperative; 09, just before perfusion; 2459, halfway perfusion; 219, just before release of the tourniquet; 59 (109 and 309), 5 (10 and 30) minutes
after release of the tourniquet; 3h and 7h, 3 and 7 hours after ILP; d1 to d7, number of days after ILP.
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In our patients, the necessity for dopamine administration
was not related to the highest levels of TNFa in the sys-
temic circulation. This finding is in accordance with previ-
ous studies in which no correlation between maximum
TNFa concentrations in the peripheral blood of an individ-
ual and the side effects could be found,20,23 which indicates
that patients vary in their sensitivity to TNFa.
Systemic toxicity seems to be determined by the du-
ration of exposure to high levels of TNFa. Our data
demonstrate this clearly, with levels of 1,000 to more
than 100,000 pg/ml for 4 hours in high leakage patients,
and only “moderate” levels (;1,000 pg/ml for 20 min-
utes) in nonleakage patients. In nonleakage patients, 20
minutes of “moderate” TNF levels were not enough to
cause hypotension. This is in accordance with the find-
ings reported previously in this journal by Vrouenraets et
al.,24 who described minimal toxicity after leakage-con-
trolled ILP in 20 patients. The IL-6 curves demonstrate
the effect of prolonged exposure to high TNF levels even
more pungently. Even at 24 hours after ILP, IL-6 levels
are still higher in the leakage patients than the peak IL-6
levels observed in ILP patients without leakage. IL-6
levels remained elevated for at least 3 whole days.
In the 10 patients with high leakage, 4 hours of expo-
sure to very high levels of TNFa resulted in three pa-
tients with grade II and four patients with grade III
hypotension. Four patients required dopamine support
temporarily with good response. In phase I–II studies on
the systemic administration of TNFa, dose-limiting tox-
icity was observed at TNF concentrations similar to
those observed in our 10 patients described here. For
instance, Schaadt et al.22 reported dose-limiting hypoten-
sion in 32% of the patients after administration of 650
mg/m2 intravenously, resulting in a systemic TNF peak
concentration of approximately 270 ng/ml. Moreover,
grade II hepatotoxicity was observed in 80% of the
patients. This is quite different from the relative lack of
toxicity observed in our 10 ILP patients who had similar
systemic TNF peak concentrations. In other studies, hy-
potension was dose limiting at lower doses, with serum
TNF levels of 10 ng/ml.8,9
In comparison with septic shock, the duration of expo-
sure to elevated levels of TNFa in the leakage patients is
relatively short. The prolonged exposure in septic shock,
despite concentrations many times lower than the short
peak levels after ILP, results in the typically unresponsive-
ness of the hypotension to fluid challenge in the septic
shock patients.25–28 Adequate diuresis plays a key role to
keep the period of high circulating TNF levels as short as
possible, to prevent a septic shock-like state in perfusion
patients. That patients are well hydrated at the time of
exposure to TNF, and that their blood pressure is optimally
maintained by fluid challenge, and only if necessary also by
the use of dopamine, prevents a septic shock-like situation.
This explains why these patients have little toxicity in view
of the very high circulating TNF levels. It is a fundamental
difference, with often poorly hydrated patients with meta-
static cancer who received intravenous TNFa in phase I-II
studies in the past. Moreover, septic patients are infected
and have significant levels of endotoxin, which has been
shown to be synergistic with TNFa for toxicity (in rats).29,30
In addition, Feelders et al.31 have shown that, in patients
who underwent ILP, cortisol is already increased before the
TNF peak as a result of surgery and anesthesia. The cortisol
response may have a down-regulatory effect on TNFa.
The increased TNFa levels in the patients with sys-
temic leakage were followed by significantly higher lev-
els of IL-6 and IL-8. This is in accordance with previous
studies.18,20,32 In our study, we also determined CRP and
sPLA2 as variables of the acute phase response. sPLA2
levels were more increased in the leakage patients; CRP,
in contrast, had significantly lower levels in these pa-
tients at the time points of maximum values. Lower
levels of CRP than expected were also observed in pa-
tients who underwent an isolated hepatic perfusion.33
That CRP had even lower levels in leakage patients
could be ascribed to a higher expenditure of CRP in the
TABLE 3. Median and range of peak levels of cytokines and acute phase proteins in 10 patients undergoing ILP with more
than 10% leakage compared with 9 patients without leakage in the systemic circulation
Cytokine/acute
phase protein Time point
Leakage patients,
median (range)
No leakage, median
(range) P
TNFa, ng/ml 10 min after ILP 108 (26–277) 1.4 (0.3–3.4) ,.001
IL-6, ng/ml 3 h after ILP 49 (13–257) 0.8 (0.3–3.3) ,.001
IL-8, ng/ml 3 h after ILP 14 (1.3–49) 0.2 (0.01–1.7) ,.001
CRP, mg/l Day 1 76 (34–419) 166 (93–350) ,.01
sPLA2, ng/ml Day 1 568 (123–986) 84 (20–390) ,.01
ILP, isolated limb perfusion; TNFa, tumor necrosis factor-a; IL-6 and IL-8, interleukin-6 and interleukin-8; CRP, C-reactive protein; sPLA2,
s-phospholipase A2.
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neutralization of the effects of exposure to higher levels
of TNFa.34–36
In conclusion, ILP, complicated by high leakage to the
systemic circulation, resulted in high systemic levels of
TNFa up to 277 ng/ml. IL-6 and IL-8 followed with
significantly higher levels compared with values mea-
sured in patients without leakage. The patterns of the
APPs CRP and sPLA2 resembled each other, except that
CRP had significantly lower maximum levels in leakage
patients compared with patients without leakage. Over-
all, the patients with high systemic leakage had a marked
mild clinical course. It is our experience that, even in
patients with very high leakage, life-threatening reac-
tions have not occurred and that temporary hypotension
can be easily dealt with by fluid challenge and some-
times by temporary vasopressor support. Our observa-
tions support the need for further study of the potential
use of TNFa systemically.
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